149 related articles for article (PubMed ID: 36357573)
21. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
[TBL] [Abstract][Full Text] [Related]
22. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
23. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Yeung YA; Krishnamoorthy V; Dettling D; Sommer C; Poulsen K; Ni I; Pham A; Chen W; Liao-Chan S; Lindquist K; Chin SM; Chunyk AG; Hu W; Sasu B; Chaparro-Riggers J; Djuretic I
Mol Ther; 2020 Mar; 28(3):889-900. PubMed ID: 31981494
[TBL] [Abstract][Full Text] [Related]
24. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
Walter RB
Expert Rev Hematol; 2014 Jun; 7(3):317-9. PubMed ID: 24617311
[TBL] [Abstract][Full Text] [Related]
25. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
26. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.
Aliperta R; Cartellieri M; Feldmann A; Arndt C; Koristka S; Michalk I; von Bonin M; Ehninger A; Bachmann J; Ehninger G; Bornhäuser M; Bachmann MP
Blood Cancer J; 2015 Sep; 5(9):e348. PubMed ID: 26383821
[TBL] [Abstract][Full Text] [Related]
27. A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies.
Shepherd A; Bennychen B; Marcil A; Bloemberg D; Pon RA; Weeratna RD; McComb S
PLoS One; 2023; 18(6):e0273884. PubMed ID: 37347762
[TBL] [Abstract][Full Text] [Related]
28. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Bonnevaux H; Guerif S; Albrecht J; Jouannot E; De Gallier T; Beil C; Lange C; Leuschner WD; Schneider M; Lemoine C; Caron A; Amara C; Barrière C; Siavellis J; Bardet V; Luna E; Agrawal P; Drake DR; Rao E; Wonerow P; Carrez C; Blanc V; Hsu K; Wiederschain D; Fraenkel PG; Virone-Oddos A
Oncoimmunology; 2021; 10(1):1945803. PubMed ID: 34484869
[TBL] [Abstract][Full Text] [Related]
29. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
30. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.
Guy DG; Uy GL
Curr Hematol Malig Rep; 2018 Dec; 13(6):417-425. PubMed ID: 30280288
[TBL] [Abstract][Full Text] [Related]
31. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
Arndt C; von Bonin M; Cartellieri M; Feldmann A; Koristka S; Michalk I; Stamova S; Bornhäuser M; Schmitz M; Ehninger G; Bachmann M
Leukemia; 2013 Apr; 27(4):964-7. PubMed ID: 23325142
[No Abstract] [Full Text] [Related]
32. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
Hays P
Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
[TBL] [Abstract][Full Text] [Related]
33. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
Bartels L; de Jong G; Gillissen MA; Yasuda E; Kattler V; Bru C; Fatmawati C; van Hal-van Veen SE; Cercel MG; Moiset G; Bakker AQ; van Helden PM; Villaudy J; Hazenberg MD; Spits H; Wagner K
Cancer Res; 2019 Jul; 79(13):3372-3382. PubMed ID: 31064847
[TBL] [Abstract][Full Text] [Related]
34. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
35. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
36. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia.
Fasslrinner F; Arndt C; Koristka S; Feldmann A; Altmann H; von Bonin M; Schmitz M; Bornhäuser M; Bachmann M
Br J Haematol; 2019 Sep; 186(5):735-740. PubMed ID: 31119728
[TBL] [Abstract][Full Text] [Related]
37. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukemia targets for bispecific antibodies.
Hoseini SS; Cheung NK
Blood Cancer J; 2017 Feb; 7(2):e522. PubMed ID: 28157217
[TBL] [Abstract][Full Text] [Related]
39. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
Wu J; Fu J; Zhang M; Liu D
J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
[TBL] [Abstract][Full Text] [Related]
40. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C; Polerà N; Di Martino MT; Juli G; Hokanson CA; Odineca T; Signorelli S; Grillone K; Ascrizzi S; Mancuso A; Staropoli N; Caparello B; Cerra M; Nisticò G; Tagliaferri P; Crea R; Caracciolo D; Tassone P
J Transl Med; 2023 May; 21(1):301. PubMed ID: 37143061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]